[go: up one dir, main page]

AR063219A1 - Derivados de azetidinona, una composicion que los comprende y su uso en el tratamiento del dolor y de trastornos del metabolismo lipidico. - Google Patents

Derivados de azetidinona, una composicion que los comprende y su uso en el tratamiento del dolor y de trastornos del metabolismo lipidico.

Info

Publication number
AR063219A1
AR063219A1 ARP070104078A ARP070104078A AR063219A1 AR 063219 A1 AR063219 A1 AR 063219A1 AR P070104078 A ARP070104078 A AR P070104078A AR P070104078 A ARP070104078 A AR P070104078A AR 063219 A1 AR063219 A1 AR 063219A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkylene
aryl
group
optionally
Prior art date
Application number
ARP070104078A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR063219A1 publication Critical patent/AR063219A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Derivados de azetidinona, a composiciones que comprenden un derivado de azetidinona y a su uso para tratar o prevenir un trastorno del metabolismo lipídico, dolor, diabetes, una afeccion vascular, desmielinizacion o enfermedad hepática grasa no alcoholica. Reivindicacion 1: Un compuesto que tiene la formula (1) o su sal, solvato, éster, profármaco o estereoisomero aceptable para uso farmacéutico, donde: R1 es H, alquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, difenilmetilo, cicloalquilalquilo, cicloalquilo, cicloalquenilo, heterocicloalquilo, heterocicloalquenilo o -alquilen-C(O)N(alquilo)2, donde un grupo alquilo, arilo o heteroarilo puede estar opcional e independientemente sustituido con uno o más de los siguientes grupos: -(C=NO-alquil)CH3, -NC(O)NH2, -NC(O)NH(alquilo), -NC(O)N(alquilo)2, -SO2NH2, -SO2NH(alquilo), -SO2N(alquilo)2, -CF3, -OH, -halo, -CN, -alcoxi, -C(O)O-alquilo, -S(O)alquilo, -SO2-alquilo o -P(O)(O-alquilo)2, y un grupo arilo además puede estar opcional e independientemente sustituido con uno o más grupos alquilo; R2 es H, alquilo, cicloalquilo, arilo, arilalquilo, heteroarilalquilo, heterocicloalquilo, heterocicloalquilalquilo, R6-A-, alquil-O-C(O)-, (alquil)2N-alquilen-C(O)-, (alquil)2-N-C(O)-alquilen-C(O)-, CN-alquilen-C(O)-, alquil-Oalquilen-C(O)-, alquil-C(O)-alquilen-C(O)-, alquil-C(O)-NH-alquilen-C(O)-, alquil-NH-C(O)-, aril-NH-C(O)-, alquil-O-C(O)-alquilen-C(O)-, alquil-O-C(O)-cicloalquilen-alquilen-, NH2-C(O)-NH- alquilen-C(O)-, NH2-C(O)-alquilen-C(O)-, alquil-C(O)-NH-alquilen-S-alquilen-C(O)-, alquil-O-C(O)-alquilen-C(O)-, alquil-S-alquilen-C(O)-, alquil-C(O)-cicloalquilen-alquilen-C(O)-, alquil-S-alquileno-, (-NHC(O)alquil)C(O)-, alquil(-C(O)Oalquil)-NH- C(O)- o -C(O)-alquilen-N(R6)2-; o alquil-S-alquilen(-NHC(O)alquil-C(O)-, donde un grupo alquilo o arilo puede estar opcional e independientemente sustituido con uno o más de los siguientes grupos; -(C=N-O-alquil)CH3, -NH-C(O)NH-alquilo, -C(O)NH2, - CN, -C(O)NH-alquilo, -C(O)O-alquilo, -C(O)H, -C(O)OH, -NC(O)NH2, -NC(O)NH(alquilo), -NC(O)N(alquil)2, -SO2NH2, -SO2NH(alquilo), -SO2N(alquilo)2, -CF3, -OH, -halo, haloalquilo, -CN, -alcoxi, -C(O)O-alquilo, -S(O)alquilo, -SO2-alquilo o -P(O)(O- alquilo)2, y un grupo arilo además puede estar opcional e independientemente sustituido con uno o más grupos alquilo; R3 es H, alquilo, arilo, arilalquilo, arilalquenilo, arilalquinilo, NH-arilalquilo, arilalcoxi, ariltio, arilalquiltio, arilcarbonilo, ariloxi, cicloalquilo, arilsulfonilo, heteroarilo, heteroarilalquilo, heteroarilalquenilo, heteroarilalquinilo, heteroarilalcoxi, heteroariloxi o heteroarilsulfonilo, donde un grupo alquilo o arilo puede estar opcional e independientemente sustituido con uno o más de los siguientes grupos; -(C=N-O-alquil)CH3, -NC(O)NH2, -NC(O)NH(alquilo), -NC(O)N(alquilo)2, -SO2NH2, -SO2NH(alquilo), -SO2N(alquilo)2, -CF3, -OH, -halo, -CN, -alcoxi, -C(O)O-alquilo, -S(O)alquilo, -SO2- alquilo o -P(O)(O-alquilo)2, un grupo arilo puede estar opcional e independientemente sustituido con uno o más grupos alquilo, y un grupo heteroarilo puede estar opcional e independientemente sustituido con uno o más grupos arilo o heteroarilo. cada aparicion de R4 y R5 es independientemente -C(R7)2-, donde el átomo de carbono en el anillo de un grupo y el átomo de carbono en el anillo de un grupo puede estar opcionalmente unido por un grupo -CH2-CH2-; cada aparicion de R6 es independientemente alquilo. alquenilo, arilo, heteroarilo, cicloalquilo, cicloalquilalquilo, heterocicloalquilo, cicloalquenilo, heterocicloalquenilo, cicloalquilo benzofusionado, heterocicloalquilo benzofusionado, o heterocicloalquenilo benzofusionado; cada aparicion de R7 es independientemente -H, -alquilo, -CN u -OH; A es -C(O)-, -OC(O)-, -alquilen-C(O)-, -O-alquilen-C(O)-, -C(O)-alquilen-C(O)-, -C(O)-NHCH2-C(O)-, -C(O)-N(alquil)-CH2-C(O)-, -alquilen-, -alquenileno, -alquenilen-C(O)-, grupo de formula (2), -O- C(O)-alquilen-C(O)-, -cicloalquilen-NH-C(O)-, -NHC(O)-, -alquilen-NHC(O)-, -alquilen-C(O)NH-alquilen-C(O)-, -alquilen-C(O)NH-alquilen-C(O)-, -C(O)-NH-alquilen-C(O)-, -alquilen-O-alquilen-C(O)-, -alquilen(alcoxi)-C(O)- o -S-alquilen-C(O)-, donde un grupo A está unido al átomo de nitrogeno al cual está unido mediante un grupo C(O) terminal; u es un entero que varia de 0 hasta 3; y v es un entero que varía de 0 hasta 3; de modo que la suma de u y v es de 3 a 5, de modo que el compuesto de formula (1) no es un compuesto de formula (1A), (1B), (1C) o (1D) como se expone en la memoria descriptiva anterior.
ARP070104078A 2006-09-15 2007-09-14 Derivados de azetidinona, una composicion que los comprende y su uso en el tratamiento del dolor y de trastornos del metabolismo lipidico. AR063219A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84507506P 2006-09-15 2006-09-15

Publications (1)

Publication Number Publication Date
AR063219A1 true AR063219A1 (es) 2009-01-14

Family

ID=39145026

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104078A AR063219A1 (es) 2006-09-15 2007-09-14 Derivados de azetidinona, una composicion que los comprende y su uso en el tratamiento del dolor y de trastornos del metabolismo lipidico.

Country Status (9)

Country Link
US (1) US7884080B2 (es)
EP (1) EP2061792A2 (es)
JP (1) JP2010503677A (es)
CN (1) CN101583612A (es)
AR (1) AR063219A1 (es)
CA (1) CA2663502A1 (es)
MX (1) MX2009002921A (es)
TW (1) TW200819450A (es)
WO (1) WO2008033464A2 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2663500A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism
CA2663434A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders
KR20090071589A (ko) * 2006-09-15 2009-07-01 쉐링 코포레이션 통증 및 지질 대사 장애의 치료에 유용한 아제티딘 및 아제티돈 유도체
EP2091534A1 (en) * 2006-09-15 2009-08-26 Schering Corporation Azetidinone derivatives and methods of use thereof
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20090092693A1 (en) * 2007-10-05 2009-04-09 Mady Attila Platelet manipulation to prevent and treat endovascular disease and its sequelae, to prevent and treat arrhythmias and to prevent malignancy
MX2010012080A (es) * 2008-05-05 2011-04-11 Univ Winthrop Hospital Metodo para mejorar el perfil de riesgo cardiovascular de los inhibidores de cox.
KR101769999B1 (ko) 2008-09-18 2017-08-21 노오쓰웨스턴 유니버시티 Ｎｍｄａ 수용체 조절제 및 그의 용도
US20120083476A1 (en) 2009-06-05 2012-04-05 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
CN102933226A (zh) 2010-02-11 2013-02-13 西北大学 二级结构稳定化的nmda受体调节剂及其用途
ES2552657T3 (es) 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
TWI562977B (en) 2010-11-05 2016-12-21 Bayer Ip Gmbh Process for the preparation of substituted n-(benzyl)cyclopropanamines by imine hydrogenation
EA031618B1 (ru) 2011-06-09 2019-01-31 Ризен Фармасьютикалз Са Соединения-модуляторы gpr-119
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
SG10201406155QA (en) 2011-10-28 2014-11-27 Lumena Pharmaceuticals Inc Bile Acid Recycling Inhibitors For Treatment Of Pediatric Cholestatic Liver Diseases
SG11201401849QA (en) 2011-10-28 2014-05-29 Lumena Pharmaceuticals Inc Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
TWI630191B (zh) * 2012-04-26 2018-07-21 拜耳作物科學公司 用於製備ｎ-（５-氯-２-異丙基苄基）環丙胺之中間體、其製備方法及用途
MY177686A (en) 2012-09-27 2020-09-23 Kowa Co Therapeutic agent for dyslipidemia
WO2014120786A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
SI2951183T1 (sl) 2013-01-29 2019-07-31 Aptinyx Inc. Spiro-laktam NMDA receptorski modulatorji in njihove uporabe
US9738650B2 (en) 2013-01-29 2017-08-22 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
WO2014120784A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN105308049A (zh) 2013-01-29 2016-02-03 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
RU2015139731A (ru) 2013-03-15 2017-04-20 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециркуляции желчных кислот для лечения первичного склерозирующего холангита и воспалительного заболевания кишечника
CN105228615A (zh) 2013-03-15 2016-01-06 鲁美纳医药公司 用于治疗巴雷特食管和胃食管返流疾病的胆汁酸再循环抑制剂
WO2015111971A1 (ko) * 2014-01-23 2015-07-30 동국대학교 산학협력단 Gpr119 리간드를 유효성분으로 포함하는 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
WO2017070680A1 (en) 2015-10-22 2017-04-27 Cavion Llc Methods for treating angelman syndrome and related disorders
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2017201283A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
JP7032378B2 (ja) 2016-08-01 2022-03-08 アプティニックス インコーポレイテッド スピロ－ラクタムｎｍｄａ受容体修飾因子及びその使用
SG11201900554YA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda modulators and methods of using same
WO2018026763A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
MX383650B (es) 2016-08-01 2025-03-14 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos.
AU2017306158B2 (en) 2016-08-01 2021-10-14 Aptinyx Inc. Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof
EP3585376A4 (en) 2017-02-15 2020-11-25 Cavion, Inc. CALCIUM CHANNELS INHIBITORS
NZ758559A (en) 2017-04-26 2025-08-29 Cavion Inc Methods for improving memory and cognition and for treating memory and cognitive disorders
CN112204031B (zh) 2018-01-31 2024-05-24 元羿生物科技(香港)有限公司 螺-内酰胺nmda受体调节剂及其用途
CA3115235A1 (en) 2018-10-03 2020-04-09 Cavion, Inc. Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
EP3923943B1 (en) 2019-02-12 2024-07-31 Mirum Pharmaceuticals, Inc. Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
CA3146857A1 (en) 2019-07-11 2021-01-14 Praxis Precision Medicines, Inc. Formulations of t-type calcium channel modulators and methods of use thereof
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
WO2025255502A1 (en) 2024-06-07 2025-12-11 Cavion, Inc. PYRIDYL AMIDE Cav3 CHANNEL MODULATORS

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692515A (en) * 1984-09-24 1987-09-08 Pennwalt Corporation Adamantane-spirolactams
US5215994A (en) * 1990-09-25 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic derivatives
US5130425A (en) * 1990-10-12 1992-07-14 American Home Products Corporation Spiro-lactams and analogs thereof useful as aldose reductase inhibitors
US5688787A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
GB9201789D0 (en) 1992-01-28 1992-03-11 Fujisawa Pharmaceutical Co Heterocyclic derivatives
US5354759A (en) * 1991-09-12 1994-10-11 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic compounds
CA2131184A1 (en) * 1992-04-03 1993-10-14 Jan Willem Hubert Smeets Selective n-acylation of amino alcohols
LT3595B (en) 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
FR2710337B1 (fr) 1993-09-23 1995-12-08 Gerard Coquerel Procédé de dédoublement de deux antipodes optiques par entraînement polythermique programmé et autoensemencé.
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
US5648484A (en) * 1995-03-07 1997-07-15 Schering Corporation Catalytic enantioselective synthesis of a spriofused azetidinone
ES2177925T3 (es) * 1996-01-23 2002-12-16 Novartis Ag Pirrolopirimidinas y procedimientos para su preparacion.
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
FR2799756B1 (fr) * 1999-10-15 2001-12-14 Adir Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE10050322A1 (de) 2000-10-10 2002-04-11 Brose Fahrzeugteile Türmodulträger
BR0116325A (pt) * 2000-12-21 2003-10-14 Aventis Pharma Gmbh 1,2-difenilazetidinonas, processos para a sua preparação, medicamentos contendo estes compostos e sua aplicação para o tratamento de distúrbios do metabolismo de lipìdios
TWI291957B (en) 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
JP2003214113A (ja) * 2002-01-28 2003-07-30 Toshiba Corp 地熱タービン
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
GB0307891D0 (en) 2003-04-04 2003-05-14 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
AR041089A1 (es) * 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
EP1635813A4 (en) 2003-06-06 2009-07-01 Merck & Co Inc COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA
US20070099884A1 (en) 2003-06-06 2007-05-03 Erondu Ngozi E Combination therapy for the treatment of diabetes
US7342039B2 (en) * 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7396940B2 (en) * 2003-10-23 2008-07-08 Hoffmann-La Roche Inc. Combinatorial library of 3-aryl-1H-indole-2-carboxylic acid
EP1680189A2 (en) * 2003-11-05 2006-07-19 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
TW200538453A (en) * 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
ITMI20040874A1 (it) 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici ed azaindolici con azione antitumorale
EP1598336A1 (en) * 2004-05-20 2005-11-23 Laboratorios Del Dr. Esteve, S.A. Regioselective hydroxylation, functionalisation and protection of spirolactams
US7291728B2 (en) * 2004-05-10 2007-11-06 Laboratories Del Dr. Esteve, S.A. Spirolactams and their synthesis
CA2573185A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
KR20090071589A (ko) * 2006-09-15 2009-07-01 쉐링 코포레이션 통증 및 지질 대사 장애의 치료에 유용한 아제티딘 및 아제티돈 유도체
CA2663947A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism
CA2663434A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders
KR20090066287A (ko) * 2006-09-15 2009-06-23 쉐링 코포레이션 통증, 당뇨병, 및 지질 대사 장애의 치료방법
EP2091534A1 (en) * 2006-09-15 2009-08-26 Schering Corporation Azetidinone derivatives and methods of use thereof
CA2663500A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism

Also Published As

Publication number Publication date
JP2010503677A (ja) 2010-02-04
WO2008033464A3 (en) 2008-05-15
EP2061792A2 (en) 2009-05-27
TW200819450A (en) 2008-05-01
CN101583612A (zh) 2009-11-18
MX2009002921A (es) 2009-04-01
US20080076751A1 (en) 2008-03-27
WO2008033464A2 (en) 2008-03-20
US7884080B2 (en) 2011-02-08
CA2663502A1 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
AR063219A1 (es) Derivados de azetidinona, una composicion que los comprende y su uso en el tratamiento del dolor y de trastornos del metabolismo lipidico.
AR062793A1 (es) Compuestos de azetidinona espirociclicos y metodos para su uso
AR068106A1 (es) Derivados de indol 2-carboxi sustituidos y una composicion farmaceutica
AR081331A1 (es) Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR072559A1 (es) Amidas sustituidas, composicion farmaceutica que las comprende y su uso en el tratamiento de enfermedades mediadas por dgat1.
AR068108A1 (es) Derivados azaindol 2,3-sustituidos y una composicion farmaceutica
RU2020105929A (ru) Способы и композиции для модулирования сплайсинга
PE20252237A1 (es) Inhibidores macrociclicos de kras y metodos de uso
NZ586058A (en) Benzomorphan compounds
AR081932A1 (es) Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes
AR039659A1 (es) Inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida metaloproteinasa
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
AR058073A1 (es) Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos
AR045651A1 (es) Derivados de tiazol como moduladores del receptor de cannabinoide
AR036213A1 (es) Derivados de 6-fenil-pirrolo[2,3-d]pirimidina, un proceso para su preparacion, composicion farmaceutica y el uso de dichos derivados para la preparacion de composiciones farmaceuticas
AR044614A1 (es) Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4)
AR068503A1 (es) Derivados de amidas sustituidas, composicion farmaceutica y usos.
AR046326A1 (es) Compuestos de heteroarilo de 6-miembros para el tratamiento de trastornos neurodegenerativos
AR081626A1 (es) Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR059727A1 (es) Moduladores de 11- beta hidroxil esteriode deshidrogenasa de tipo 1, composiciones farmaceuticas de los mismos , y metodos de uso de los mismos
JP2014507421A5 (es)
AR085489A1 (es) Derivados de triazolopiridinas, composiciones farmaceuticas que los contienen, proceso para prepararlos, intermediarios de dicho proceso y uso de los mismos para el tratamiento de enfermedades autoinmunes e inflamatorias
AR073922A1 (es) 2- oxoquinoxalinas como bloqueadores de los canales de sodio tardios
AR071327A1 (es) Inhibidores de pkl y composiciones farmaceuticas que los contienen
BRPI0714553B8 (pt) derivados de camptotecina, processo para preparação dos mesmos, composição farmacêutica e seu uso

Legal Events

Date Code Title Description
FA Abandonment or withdrawal